US Public Library of Science launches rival to 'The Lancet'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A major new "open access" journal for medicine is launched today, putting it in direct competition with the established publications in this lucrative area including Reed Elsevier's The Lancet.
A major new "open access" journal for medicine is launched today, putting it in direct competition with the established publications in this lucrative area including Reed Elsevier's The Lancet.
The Public Library of Science (PLoS), a US-based not-for-profit organisation, is behind PLoS Medicine, which it said was "the most significant international general medicine journal to emerge in over 70 years". It is the second journal launched by PLoS, which established a biology publication last year.
"Open access" publishers promise a revolution in scientific and medical publishing, although so far it has a tiny proportion of the market. Unlike traditional science and medical publishing, where libraries subscribe to journals, the new model - backed by a British parliamentary committee this summer - allows readers free access to the contents of journals. Revenues come from the article's author, who pays for its publication.
The peer-reviewed PLoS Medicine is likely to be of interest beyond the world of academic publishing and medical research. Patients interested in the latest medical research will be able to read articles freely in the journal, which will contain a summary for a lay audience.
Dr Virginia Barbour, a former executive editor of The Lancet, who is a senior editor of PLoS Medicine, said the publication was aimed at everyone "from patients to professors". She said: "People do want to read about this. Talk to anyone with a chronic disease or with a child who has a serious illness."
As well as The Lancet, which is 181 years old, PLoS Medicine will take on other prestigious medical journals, such as the British Medical Journal and the New England Journal of Medicine. An individual in the UK subscribing to The Lancet could expect to pay £112 a year, while an institution would pay £499.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments